Reply to "Benralizumab As a First-line Treatment for ABPA: Is It Really Indicated?"
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Chupp G, Lugogo N, Kline J, Ferguson G, Hirsch I, Goldman M
. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019; 122(5):478-485.
DOI: 10.1016/j.anai.2019.02.016.
View
2.
Matsuura H, Fujiwara K, Omori H, Onishi K, Kuribayashi T, Mitsumune S
. Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan. Intern Med. 2020; 60(9):1443-1450.
PMC: 8170259.
DOI: 10.2169/internalmedicine.6217-20.
View
3.
Agarwal R, Dhooria S, Sehgal I, Aggarwal A, Garg M, Saikia B
. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest. 2018; 153(3):656-664.
DOI: 10.1016/j.chest.2018.01.005.
View
4.
Agarwal R, Dhooria S, Sehgal I, Aggarwal A, Garg M, Saikia B
. A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2018; 52(3).
DOI: 10.1183/13993003.01159-2018.
View
5.
Moreira A, Silva D, Reis Ferreira A, Delgado L
. Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review. Clin Exp Allergy. 2014; 44(10):1210-27.
DOI: 10.1111/cea.12333.
View